Postmarketing Surveillance Study of Atrovent® Inhaletten® in Chronic Obstructive Airways Disease

September 11, 2014 updated by: Boehringer Ingelheim

Postmarketing Surveillance Study (as Per § 67 (6) AMG [German Drug Law] of Atrovent® Inhaletten® in Chronic Obstructive Airways Disease

To obtain further information on the tolerability and efficacy of Atrovent® inhaletten® in the treatment of chronic obstructive airways disease under conditions of daily practice

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

660

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

30 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients with chronic obstructive airways disease recruited at general practitioners, pneumologists, internists

Description

Inclusion Criteria:

  • Primarily patients of both gender, older than 30 years,who suffer from chronic obstructive airways disease
  • Only patients who had not been treated with Atrovent® within the last year were to be considered for inclusion

Exclusion Criteria:

- Contraindications listed in the Instructions for Use/Summary of Product Characteristics for Atrovent® Inhaletten®

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Chronic Obstructive Airways Disease
Drug: Atrovent® Inhaletten

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Investigator assessment of improvement in the clinical picture of the course on a 6-point symptoms profile
Time Frame: Up to 4 weeks after first study drug administration
Up to 4 weeks after first study drug administration

Secondary Outcome Measures

Outcome Measure
Time Frame
Investigator assessment of tolerability on a 4-point scale
Time Frame: Up to 4 weeks after first study drug administration
Up to 4 weeks after first study drug administration
Investigator assessment of efficacy on a 4-point scale
Time Frame: Up to 4 weeks after first study drug administration
Up to 4 weeks after first study drug administration
Number of patients with adverse drug reactions
Time Frame: Up to 4 weeks after first study drug administration
Up to 4 weeks after first study drug administration
Number of patients who withdrew from the study
Time Frame: Up to 4 weeks after first study drug administration
Up to 4 weeks after first study drug administration
Number of patients who changed the concomitant medication
Time Frame: Up to 4 weeks after first study drug administration
Up to 4 weeks after first study drug administration
Number of patients who continued treatment
Time Frame: Up to 4 weeks after first study drug administration
Up to 4 weeks after first study drug administration
Patient assessment of tolerability on a 4-point scale
Time Frame: Up to 4 weeks after first study drug administration
Up to 4 weeks after first study drug administration
Patient assessment of efficacy on a 4-point scale
Time Frame: Up to 4 weeks after first study drug administration
Up to 4 weeks after first study drug administration

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Boehringer Ingelheim

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 1999

Primary Completion (Actual)

November 1, 1999

Study Registration Dates

First Submitted

September 11, 2014

First Submitted That Met QC Criteria

September 11, 2014

First Posted (Estimate)

September 12, 2014

Study Record Updates

Last Update Posted (Estimate)

September 12, 2014

Last Update Submitted That Met QC Criteria

September 11, 2014

Last Verified

September 1, 2014

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 244.2492

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pulmonary Disease, Chronic Obstructive

Clinical Trials on Atrovent® Inhaletten

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Thailand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe